Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16921630 | 0.83 | AGXT (0.46) | AGXTCCR1CCR5CCR8HSP90AB1 | |
| SCHEMBL94923 | 0.81 | AGXT (0.53) | AGXTCCR1CCR5CCR8HSP90AB1 | |
| SCHEMBL29039529 | 0.79 | AGXT (0.52) | AGXTCCR1CCR5CCR8HSP90AB1 | |
| SCHEMBL29736023 | 0.79 | AGXT (0.52) | AGXTCCR1CCR5CCR8HSP90AB1 | |
| Hydrochloric Acid SCHEMBL28303939 | 0.79 | AGXT (0.52) | AGXTCCR1CCR5CCR8HSP90AB1 | |
| SCHEMBL1731691 | 0.77 | CCR1 (0.35) | AGXTCCR1CCR5CCR8HSP90AB1 | |
| SCHEMBL12207313 | 0.77 | AGXT (0.38) | AGXTHSP90AB1MAOAHSP90AA1 | |
| SCHEMBL10440855 | 0.74 | AGXT (0.51) | AGXTCCR1CCR5CCR8HSP90AB1 | |
| SCHEMBL2740251 | 0.73 | AGXT (0.42) | AGXTMAOA | |
| SCHEMBL192172 | 0.73 | AGXT (0.42) | AGXTHSP90AB1MAOAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266958-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | AGXT 1906/4885CCR1 4568/4885CCR5 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.